Affinity DataKi: 0.360nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 0.410nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 0.530nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 0.550nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 0.600nM ΔG°: -52.6kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 0.700nM ΔG°: -52.3kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 0.720nM ΔG°: -52.2kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 2.10nMAssay Description:Inhibition of recombinant human OGA expressed in Escherichia coli assessed as inhibitory constant using 4-MUGlcNAc as substrate incubated for 20 mins...More data for this Ligand-Target Pair
Affinity DataKi: 2.30nM ΔG°: -49.3kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 2.40nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 2.52nM ΔG°: -49.1kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 2.80nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 2.82nM ΔG°: -48.8kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 3nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 3.22nM ΔG°: -48.5kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 3.30nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 4.21nM ΔG°: -47.8kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 5.30nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 5.5nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 5.60nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 7.51nM ΔG°: -46.4kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 7.90nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 9nM ΔG°: -45.9kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 9nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 9.40nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 9.5nM ΔG°: -45.8kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 10.2nM ΔG°: -45.6kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 11nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 12nM ΔG°: -45.2kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 13nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 14nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 14nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 15.6nM ΔG°: -44.6kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 18.1nM ΔG°: -44.2kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 20nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 23nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 26nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 28nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 28.1nM ΔG°: -43.1kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 29nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 31.2nM ΔG°: -42.8kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 33.3nM ΔG°: -42.7kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 33.6nM ΔG°: -42.7kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 35nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 41nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 44nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 50nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 50nMAssay Description:Inhibition of recombinant human OGAMore data for this Ligand-Target Pair
Affinity DataKi: 50.7nM ΔG°: -41.6kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair
Affinity DataKi: 52nM ΔG°: -41.6kJ/molepH: 7.4 T: 2°CAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Coagulation Factor XIa can be determined using a relevant purified serine...More data for this Ligand-Target Pair